FDA reviewer calls for approvals overhaul

One of the FDA types who reviewed Avandia is calling for entirely new procedures for evaluating diabetes drugs. In an article for Diabetes Care, Bob Misbin says new diabetes treatments shouldn't be tested against placebo, but against existing drugs.

Noting that the "Avandia affair" got out of hand, Misbin says the FDA should set a high standard for new meds. It may not be able to require new drugs to be better than existing treatments, but it should do whatever's necessary to make sure drugs are safe.

Misbin wanted to require GlaxoSmithKline to conduct a post-marketing safety study of Avandia, but his bosses rejected that idea. Now, Misbin is saying that all diabetes drugs should be studied specifically for safety--in trials that can't exclude patients at risk for serious side effects--before they're approved.

- read the item at Pharmalot

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.